Singapore markets closed

VRTX Apr 2024 350.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
76.000.00 (0.00%)
As of 10:09AM EST. Market open.
Full screen
Previous close76.00
Expiry date2024-04-19
Day's range76.00 - 76.00
Contract rangeN/A
Open interest22

    Insider Sell: EVP, Chief Technical Ops. Off. ...

    On February 21, 2024, Atkinson Edward Morrow III, EVP, Chief Technical Ops. Off. of Vertex Pharmaceuticals Inc (VRTX), sold 1,201 shares of the company.

  • Business Wire

    Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older

    LONDON, February 23, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G

  • Insider Monkey

    20 Fastest Growing Biotech Companies in the US

    In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]